Understanding the Role of Duration of Vaccine Protection with MenAfriVac: Simulating Alternative Vaccination Strategies
Open Access
- 23 February 2021
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 9 (2) , 461
Abstract
We previously developed a transmission dynamic model of Neisseria meningitidis serogroup A (NmA) with the aim of forecasting the relative benefits of different immunisation strategies with MenAfriVac. Our findings suggested that the most effective strategy in maintaining disease control was the introduction of MenAfriVac into the Expanded Programme on Immunisation (EPI). This strategy is currently being followed by the countries of the meningitis belt. Since then, the persistence of vaccine-induced antibodies has been further studied and new data suggest that immune response is influenced by the age at vaccination. Here, we aim to investigate the influence of both the duration and age-specificity of vaccine-induced protection on our model predictions and explore how the optimal vaccination strategy may change in the long-term. We adapted our previous model and considered plausible alternative immunization strategies, including the addition of a booster dose to the current schedule, as well as the routine vaccination of school-aged children for a range of different assumptions regarding the duration of protection. To allow for a comparison between the different strategies, we use several metrics, including the median age of infection, the number of people needed to vaccinate (NNV) to prevent one case, the age distribution of cases for each strategy, as well as the time it takes for the number of cases to start increasing after the honeymoon period (resurgence). None of the strategies explored in this work is superior in all respects. This is especially true when vaccine-induced protection is the same regardless of the age at vaccination. Uncertainty in the duration of protection is important. For duration of protection lasting for an average of 18 years or longer, the model predicts elimination of NmA cases. Assuming that vaccine protection is more durable for individuals vaccinated after the age of 5 years, routine immunization of older children would be more efficient in reducing disease incidence and would also result in a fewer number of doses necessary to prevent one case. Assuming that elimination does not occur, adding a booster dose is likely to prevent most cases but the caveat will be a more costly intervention. These results can be used to understand important sources of uncertainty around MenAfriVac and support decisions by policymakers.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-009125 / OPP1157270)
This publication has 19 references indexed in Scilit:
- Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trialsThe Lancet Infectious Diseases, 2019
- Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?Clinical Infectious Diseases, 2018
- Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance dataThe Lancet Infectious Diseases, 2017
- Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004–2013Clinical Infectious Diseases, 2015
- Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis BeltClinical Infectious Diseases, 2015
- Meningococcal A conjugate vaccine: updated guidance, February 2015.2015
- How and why researchers use the number needed to vaccinate to inform decision making—A systematic reviewVaccine, 2015
- Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community studyThe Lancet, 2014
- Bactericidal antibody is the immunologic surrogate of protection against meningococcal diseaseVaccine, 2009
- Meningococcal meningitis in AfricaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1999